# A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

> **NCT00902291** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 205 (actual)

## Conditions studied

- Carcinoma, Pancreatic Ductal
- Pancreatic Cancer
- Pancreatic Disease

## Interventions

- **BIOLOGICAL:** AGS-1C4D4
- **BIOLOGICAL:** Gemcitabine

## Key facts

- **NCT ID:** NCT00902291
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2015-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902291, "A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00902291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*